Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

As for Chia Tai Feng Hai, the company is owned by parent company Sino Biopharmaceutical, a large Chinese pharma based in Hong ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for approval, contradicting the biotech’s claims that the candidate’s eventual ...

Like many life sciences outfits undergoing a restructuring, Charles River Laboratories is balancing layoffs and a business ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

AI has been hailed as a way to speed up historically sluggish drug development, but an entirely AI-designed drug has yet to be approved by the FDA. The furthest along is likely Insilico Medicine’s ...

Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...